FGFR4 and chronic kidney disease: We found that hypertrophic effects of FGF23 on cardiac myocytes are reversible in vitro and in vivo, and that an isoform-specific FGFR4 blocking antibody is capable of reversing FGF23-mediated hypertrophic growth of isolated cardiac myocytes and alleviating established LVH in an animal model of CKD with high FGF23 levels.